


PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0302116-9
Patent application number

(86) Ingivningsdatum 2003-07-21
Date of filing

Stockholm, 2004-07-09

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjordis Segerlund

Avgift
Fee 170:-

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

NOT FOR PUBLICATION

NOVEL COMPOUNDS

- 5 The present invention relates to piperidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Histamine is a biogenic amine that regulates a variety of physiological and pathological processes including inflammation, gastric acid secretion and neurotransmission.


- 10 Histamine acts via a family of G-protein coupled receptors and 4 members of this family have been identified and cloned: histamine H1 (Yamashita *et al*, 1991), histamine H2 (Gantz *et al*, 1991), histamine H3 (Lovenberg *et al*, 1991) and histamine H4 receptor (Oda *et al*, 1999). H1 and H2 are the best characterised of these receptors and antagonists of both are used clinically. In general, inflammatory and allergic responses are modified by
- 15 H1 receptors (Ash and Schild, 1966) while gastric acid secretion is regulated by interaction with H2 receptors (Black *et al*, 1972). H1 antagonists are therefore used to treat a variety of allergic conditions and H2 antagonists are used to treat gastric ulcers. Histamine appears to regulate neurotransmitter release via H3 receptors (Arrang *et al*, 1983), but the role of the recently identified histamine H4 receptor is currently unknown. The histamine
- 20 H4 receptor bears sequence and pharmacological similarity to the H3 receptor, although the tissue distribution profiles of both receptors are different. The H3 receptor is abundant in the brain and neural tissue while the H4 receptor appears to be restricted to peripheral tissues. The H4 receptor has a high distribution in peripheral blood leukocytes, especially eosinophils and neutrophils and H4 mRNA expression has also been demonstrated in other
- 25 immune and inflammatory cells, including T-cells, dendritic cells, monocytes, macrophages, mast cells and epithelial cells. In addition, there is some evidence that receptor expression may be modulated by cytokine activation (Morse *et al*, 2001). The H4 receptor may therefore have a role in immune and/or inflammatory modulation.

- 30 Histamine H1 receptor antagonists are successfully used in the treatment of allergic rhinitis but provide incomplete blockade of all symptoms resulting in the need for co-administration of other agents to treat nasal congestion, usually sympathomimetic amine decongestants. Combinations of H1 and H2 antagonists also fail to give complete blockade of these effects. Similarly, although histamine contributes to many of the

physiological processes that occur in asthma, histamine H1 antagonists are not used in asthma because of inconsistent efficacy. Some further anti-inflammatory activity appears to be required to block the effects of histamine in many patho-physiological processes, implying a role for additional pro-inflammatory histamine receptors. The H4 receptor may serve such a role, and agents that interact with H4 receptors either alone, or in combination with other histamine receptors or anti-inflammatory agents, may provide enhanced efficacy in disease.

Antagonists of the histamine H4 receptor may therefore have utility in a variety of diseases or disorders. WO 02/072548 discloses a series of compounds said to be active as mediators of the histamine H4 receptor.

There is a need for further compounds having this activity, and the present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts and solvates thereof for use in the manufacture of a medicament for the treatment of diseases mediated by histamine H3 and H4:



in which:

Ar is an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which can be optionally substituted by 1-3 groups selected from C₁₋₆ alkyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, halogen, cyano, CF₃, OCF₃, C₃₋₆ cyclolalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₆ alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R¹ is hydrogen or C₁₋₆ alkyl;

X is O, NR^2 , CH_2 or SO_x

R^2 is C_{1-6} alkyl;

5

x is 0, 1 or 2;

Y is CH_2 , $\text{C}=\text{O}$, SO_2 , or $(\text{C}=\text{O})\text{NH}$;

10 Z is $(\text{CR}^3\text{R}^4)_r$ or Y and Z together form a $\text{CH}=\text{CH}$ group;

m and n are independently 0, 1, 2 or 3;

p and q are independently 0, 1 or 2;

15

r is 0, 1, 2, 3, or 4 and

R^3 and R^4 are independently hydrogen or C_{1-6} alkyl.

20 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

25 The term aryl includes phenyl and naphthyl. The term alkyl, whether alone or as part of another group, includes straight chain and branched chain alkyl groups. Examples of 5- to 7-membered heteroaromatic ring containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl..

30 Examples of suitable bicyclic rings include indole, benzothiphenene, quinoline, benzodioxan, and naphthyl. Examples of suitable tricyclic rings include dibenzofuran and thiene[2,3-b]benzothiophene. For any of these mono- bicyclic or tricyclic rings, substituents can be present in any suitable ring position including suitable substituents on nitrogen atoms.

35 Preferably Ar^1 is phenyl, furyl or thienyl optionally substituted as defined above. More preferably Ar^1 is phenyl optionally substituted as defined above. Preferred substituents

include halogen such as iodo, chloro and fluoro, cyclohexyl, methyl, ethyl, propyl, t-butyl, ethynyl, propenyloxy, hydroxyl, methoxy, nitro, tosyl, trifluoromethyl, thienyl, benzyl, cyano, phenylethynyl, nitrophenyl, methylthio, propoxy, butoxy, 2-propenyl, or trifluomethoxy.

5

Most preferably Ar¹ is phenyl substituted by bromo, hydroxyl or 2,4-difluoro.

Preferably R¹ is hydrogen or methyl.

10

Preferably X is O.

Preferably Y is CH₂ or C=O and Z is CH₂, CHMe, CH₂CHMe or Y and Z form a CH=CH group.

15

More preferably Y is CH₂ or C=O and Z is CH₂.

Preferably m is 1 and n is 0.

Preferably p and q are both 1.

20

Preferred compounds of the invention include:

4-(1*H*-Imidazol-4-ylmethoxy)-1-(1-oxo-3-phenylbutyl)-piperidine

4-(1*H*-Imidazol-4-ylmethoxy)-1-[[4-(trifluoromethyl)phenyl]acetyl]-piperidine

1-[2-(4-Hydroxyphenyl)-1-oxopropyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-

25

piperidine

1-[(4-fluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

1-[(2-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

1-[(4-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

4-(1*H*-imidazol-4-ylmethoxy)-1-(phenylacetyl)-piperidine

30

1-(4-cyclohexylbenzoyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

1-[(3,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)acetyl]-piperidine

1-[(3,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine


- 1-[(2,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4'-propyl[1,1'-biphenyl]-4-yl)carbonyl]-piperidine
1-[2-(4-hydroxyphenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2*E*)-3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-4-(1*H*-imidazol-4-ylmethoxy)-
5 piperidine
1-[3-(2,4-dichlorophenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2-Bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(3-Bromo-2-thienyl)methyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine
10 1-[(3-bromo-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(4-ethynylphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-(4-methylphenoxy)phenyl]methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(2-propenyloxy)phenyl]methyl]-piperidine
4-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
15 4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-methoxyphenyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-(4-methoxyphenoxy)phenyl]methyl]-piperidine
1-[(2,3-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2-chloro-4-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-(2-dibenzofuranylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
20 4-(1*H*-imidazol-4-ylmethoxy)-1-[[2-(methylthio)phenyl]methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(thieno[2,3-*b*][1]benzothien-2-ylmethyl)-piperidine
1-[(2-chloro-5-nitrophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1*H*-pyrrole, 2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-[(4-
methylphenyl)sulfonyl]-
25 2-ethoxy-6-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
1-(1,3-benzodioxol-5-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(phenylmethoxy)phenyl]methyl]-piperidine
1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(4-bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
30 4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)methyl]-piperidine

- 4-(1*H*-imidazol-4-ylmethoxy)-1-(2-thienylmethyl)-piperidine
1-[(4-chlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2-chloro-6-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-methyl-2-thienyl)methyl]-piperidine
5 4-(1*H*-imidazol-4-ylmethoxy)-1-(2-naphthalenylmethyl)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(1-naphthalenylmethyl)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-nitrophenyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(3-thienylmethyl)-piperidine
1-[(1,1'-biphenyl)-4-ylmethyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
10 1-[(2,5-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-phenoxyphenyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-methylphenyl)methyl]-piperidine
1-(2-furanyl)methyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2,6-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
15 1-[(4-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(3-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-(3-furanyl)methyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(4-ethylphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-methylphenyl)methyl]-piperidine
20 1-[(3-chlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(5-methyl-2-thienyl)methyl]-piperidine
1-[(4-bromo-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2,2'-bithiophen)-5-ylmethyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
3,5-dichloro-2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
25 1-[(3,4-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(3,5-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-
piperidine
30 4-(1*H*-imidazol-4-ylmethoxy)-1-[(1-methyl-1*H*-pyrrol-2-yl)methyl]-piperidine

- 1*H*-indole, 3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-(phenylmethyl)-
1-[(5-chloro-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-(1,3-benzodioxol-4-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
2-thiophenecarbonitrile, 3-[[4-[[4-(1*H*-imidazol-4-ylmethoxy)-1-
5 piperidinyl]methyl]phenoxy]methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(phenylethynyl)-2-thienyl]methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(4-nitrophenyl)-2-furanyl]methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(3-nitrophenyl)-2-furanyl]methyl]-piperidine
1-[(4-chloro-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
10 1-[(4-bromo-1-methyl-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(4-bromo-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-benzonitrile
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-iodophenyl)methyl]-piperidine
1-[(5-ethyl-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
15 4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(methylthio)-2-thienyl]methyl]-piperidine
1-[[1-(3,5-dichlorophenyl)-1*H*-pyrrol-2-yl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-
piperidine
1-[[1-(4-chlorophenyl)-1*H*-pyrrol-2-yl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(phenylethynyl)-2-thienyl]methyl]-piperidine
20 4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-phenoxy-2-thienyl]methyl]-piperidine
1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-propoxyphenyl)methyl]-piperidine
2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
1-[(2,4-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
25 3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-thiophenecarbonitrile
1-(benzo[*b*]thien-3-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
2-chloro-3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-pyridine
3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-(2-propenyl)-phenol
1-[(4-chloro-3-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
30 4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(trifluoromethoxy)phenyl]methyl]-piperidine

1-[(2,6-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(4-bromo-2-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(4-butoxyphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[(2,3,5-trichlorophenyl)methyl]-piperidine
 1-[(2,5-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[2-(trifluoromethyl)phenyl]methyl]-piperidine
 1-[(4-chloro-2-nitrophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 and pharmaceutically acceptable salts and solvates thereof.

Certain compounds of formula (I) are novel, and all novel compounds of formula (I) form a further aspect of the invention. The invention therefore provides a compound of formula (IA):



(IA)

in which:

Ar is an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which can be optionally substituted by 1-3 groups selected from C₁₋₆ alkyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, halogen, cyano, CF₃, OCF₃, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₆ alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R¹ is hydrogen or C₁₋₆ alkyl;

X is O, NR², CH₂ or SO_x

R² is C₁₋₆ alkyl;

x is 0, 1 or 2;

Y is C=O, SO₂, or (C=O)NH;

5

Z is (CR³R⁴)_r or Y and Z together form a CH=CH group;

m and n are independently 0, 1, 2 or 3;

10

p and q are independently 0, 1 or 2;

r is 0, 1, 2, 3, or 4, and

R³ and R⁴ are independently hydrogen or C₁₋₆alkyl.


15

For compounds (IA) Y is preferably C=O. Other preferred substituents for compounds of formula (IA) are those defined above.

20

According to the invention there is also provided a process for the preparation of compounds (I)/(IA) which comprises:


(a) for compounds of formula (I) where Y is C=O, reaction of a compound of formula (II):



(II)

30

in which R¹, X, m, n, p and q are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (III):



in which Ar, R³, R⁴ and r are as defined in formula (I) or are protected derivatives thereof,
or

- 5 (b) for compounds of formula (I) where Y is SO₂, reaction of a compound of formula (II) with a compound of formula (IV):



- 10 in which Ar, R³, R⁴ and r are as defined in formula (I) or are protected derivatives thereof,
or

(c) for compounds of formula (I) where Y is CONH, reaction of a compound of formula (II) with a carbonyl source such as phosgene or triphosgene and an amine

- 15 Ar-(CR³R⁴)_r-NH₂ or by treating with an isocyanate Ar-(CR³R⁴)_r-NCO, or

(d) for compounds of formula (I) where r is 0 and Y is CH₂, reaction of a compound of formula (II) with a compound ArCHO by reductive amination,

- 20 and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt.

- 25 The reaction between compounds (II) and (III) may be carried out using standard coupling conditions for example using peptide coupling reagents such as HOBt, DCC PyBrop, or via an acid chloride in the presence of a base such as triethylamine in an inert solvent.


Reaction of compounds (II) and (IV) can be carried out in the presence of a base such as triethylamine or pyridine in an aprotic solvent such as dichloromethane.

30 Process (d) can be carried out by reductive amination using reagents such as solid supported cyanoborohydride resin, catalytic acetic acid in aprotic solvent such as dichloromethane or NMP, or alternatively sodium triacetoxyborohydride in dichloromethane with catalytic acetic acid.

35


PRV 03-07-21

Compounds of formula (II) where X is NH₂ or SH may be prepared from compounds of formula (V)



(V)


where R¹ and m are as defined above and L is a leaving group by reaction with a compound of formula (VI):



(VI)

where X is NH₂ or SH, PG is a protecting group, L is a leaving group, and n, p and q and are as defined in formula (I), and where X is SH optionally oxidising the resulting compound of formula (II). The reaction can be carried out using an aprotic base such as triethylamine or Hunig's base in a suitable solvent such as dichloromethane. Suitable protecting groups PG include acid labile groups such as tBoc. Compounds of formula (II) where X is S can be oxidised using oxone or mCPBA under controlled conditions to give the corresponding compounds where X is SO or SO₂.

Compounds of formula (II) where X is O can be prepared by reacting a compound of formula (V) as defined above with a compound of formula (VII):



(VII)

in which PG is a protecting group, L is a leaving group, and n, p and q and are as defined in formula (I). Preferably L in compound (V) is halide or a triflate, the reaction being carried out in the presence of a base such as sodium hydride or potassium t-butoxide. The group PG is an acid labile group such as t-Boc.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of histamine H₄, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals including:

- (1) (the respiratory tract) obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;

- (2) **(bone and joints)** gout, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** pruritis, scleroderma, otitis, psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis, lupus;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **(central and peripheral nervous system)** Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; stroke and connective tissue diseases such as meningitis
- (6) **(other tissues and systemic disease)** hepatitis, vasculitis, spondyloarthropathies, vaginitis, glomerulonephritis, myositis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous

leprosy, and idiopathic thrombocytopenia pupura; post-operative adhesions, and sepsis.

(7) (allograft and xenograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;

(8) Cancer, carcinoma & tumour metastasis, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma. Hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B cell lymphoma and Burkett's lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia. Hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia. Tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.

(9) All diseases that result from a general imbalance of the immune system and resulting in increased atopic inflammatory reactions.

(10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.

(11) Burn wounds & chronic skin ulcers

(12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)

(13) thrombosis

(14) infectious diseases such as HIV infection and other viral infections, bacterial infections.

Thus, the present invention provides a compound of formula (IA), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat respiratory diseases. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.

5

In a further aspect, the present invention provides the use of a compound of formula (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

10

In a still further aspect, the present invention provides the use of a compound of formula (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of histamine H4 receptor activity is beneficial.

15

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

20

The invention still further provides a method of treating a histamine H4 mediated disease, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

25

The invention also provides a method of treating a respiratory disease, such as asthma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I) or (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

30

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

35

The compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active

ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.


The present invention also provides a pharmaceutical composition comprising a compound of formula (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (IA), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

The compounds of the invention can be administered in combination with other agents such as long-acting β -agonists.


The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The following examples illustrate the invention.

PREPARATION OF INTERMEDIATES**1-Piperidinecarboxylic acid, 4-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methoxy]-, 1,1-dimethylethyl ester**


To a solution of 4-hydroxy-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester (9.5g, 0.047mol) in dry N-methylpyrrolidine (NMP) (50ml) was added sodium hydride (60% in oil) portionwise (1.88g, 0.047mol). The mixture was allowed to stir for 30 minutes, then 4-(chloromethyl)-1-(triphenylmethyl)-1H-imidazole (ref : WO0244141) (16.8g, 0.047mol) was added and the mixture heated to 50°C for 30 min, poured into ice water and extracted with ethyl acetate. The organic extracts were washed with water and purified by flash column chromatography eluting with 1% methanolic ammonia/dichloromethane to give a solid (5.5g). 300 MHz ¹H NMR (CDCl₃) 7.41 (1H, d), 7.32-7.13 (15H, m), 6.81 (1H, bs), 4.49 (2H, s), 3.82-3.77 (2H, m), 3.62-3.54 (1H, m), 3.05-2.96 (2H, m), 1.85-1.76 (2H, m), 1.57-1.48 (2H, m), 1.45 (9H, s)

20 1-Piperidinecarboxylic acid, 4-[[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]methoxy]-, 1,1-dimethylethyl ester




This was prepared by the method of Example 1 from 4-(chloromethyl)-5-methyl-1-(triphenylmethyl)-1*H*-imidazole (ref: European Journal of Medicinal Chemistry (1990), 25(7), 557). 300 MHz ¹H NMR (CDCl₃) 7.34-7.29 (15H, m), 7.26 (1H, d), 4.47 (2H, s), 3.82-3.77 (2H, m), 3.62-3.54 (1H, m), 3.05-2.96 (2H, m), 2.25 (3H, s), 1.85-1.76 (2H, m), 1.57-1.48 (2H, m), 1.45 (9H, s)

4-[[1-(Triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-piperidine



Trimethylsilyliodide (3.3ml, 1 eq.) was added to a solution of 1-piperidinecarboxylic acid, 4-[[1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-, 1,1-dimethylethyl ester (12g, 0.023mol) at 0 – 5°C, stirred at this temperature for 30minutes, quenched with ice cold sodium bicarbonate solution and the organic layer separated, dried over sodium sulphate and evaporated. The residue was purified by flash column chromatography eluting with 5% methanolic ammonia/dichloromethane to give a solid (6.9g). 300 MHz ¹H NMR (CDCl₃) 7.41 (1H, d), 7.11-7.39 (15H, m), 6.81 (1H, d), 4.48 (2H, s), 3.53 (1H, m), 3.41 (2H, s), 3.08 (2H, m), 2.67 (2H, m), 1.99 (2H, m), 1.51 (2H, m)

4-[[5-Methyl-1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-piperidine



This was prepared by the method of example 2. MS (+APCI) m/z 438 ($M+H^+$)


5

PREPARATION OF FINAL PRODUCTS

Example 1

10

4-(1*H*-Imidazol-4-ylmethoxy)-1-(1-oxo-3-phenylbutyl)-piperidine




- 15 Bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop™) (0.55g, 1.18mmol) was added to a solution of 4-[[1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-piperidine (0.5g, 1.18mmol) and 3-phenylbutanoic acid (0.24g, 1.18mmol), Hunig's base (1 ml) in dry NMP. The mixture was stirred at room temp for 16h, evaporated and the residue dissolved in methanol, filtered through sulphonic acid ion exchange resin eluting with
- 20 methanol followed by methanolic ammonia, and evaporated. The residue was purified by reverse phase HPLC on an Xterra™ column eluting with acetonitrile/aqueous ammonium hydroxide to give the product as a white solid (0.052g). MS (+APCI) m/z 328 ($M+H^+$). 400 MHz 1H NMR (d_6 -DMSO) (@125C – spectrum at room temperature complicated due to rotamers) 7.54 (1H, s), 7.29-7.24 (3H, m), 7.19-7.14 (2H, m), 6.91 (1H, s), 4.42 (2H, s).

3.75-3.58 (2H, m), 3.30-3.08 (2H, m), 2.8 (1H, br.s), 2.61 (2H, dd), 2.53 (4H dd), 1.80-1.70 (2H, m), 1.47-1.33 (H, m), 1.25 (2H, d)

Example 2


4-(1*H*-Imidazol-4-ylmethoxy)-1-[[4-(trifluoromethyl)phenyl]acetyl]-piperidine



The title compound was prepared using the method of Example 1 with 4-(trifluoromethyl)phenyl]acetic acid : MS (+APCI) m/z 368 ($M+H^+$). 400 MHz 1H NMR (d_6 -DMSO) (@ 125C – spectrum at room temperature complicated due to rotamers) 7.63 (2H, d), 7.57 (1H, s), 7.44 (2H, d), 7.02 (1H, br.s), 4.44 (2H, s), 3.83 (2H, s), 3.80-3.73 (1H, m), 3.70-3.62 (2H, m), 3.31-3.22 (2H, m), 2.88 (2H, br.s), 1.83-1.73 (2H, br.m), 1.50-1.41 (2H, br.m)

Example 3






1-[2-(4-Hydroxyphenyl)-1-oxopropyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine



This was prepared by the method of Example 1 using 2-(4-hydroxyphenyl)propanoic acid and 4-[[5-methyl-1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-piperidine. MS (+APCI) m/z 344 ($M+H^+$). 400 MHz 1H NMR (d_6 -DMSO) 11.45 (1*H*, s), 8.96 (1*H*, s), 7.32 (1*H*, s), 6.96 (2*H*, m), 6.68 (2*H*, m), 4.30 (2*H*, s), 3.93 (1*H*, s), 3.71 (2*H*, m), 3.46 (1*H*, m), 3.25 (2*H*, m), 2.09 (3*H*, s), 1.63 (2*H*, m), 1.23 (5*H*, m)


The compounds in Table 1 were prepared using the method of Example 1 with the appropriate acid :

Table 1

Example structure	Example no.	Name	$M+H^+$ (+APCI)
	4	piperidine, 1-[(4-fluorophenyl)acetyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	317
	5	piperidine, 1-[(2-chlorophenyl)acetyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	333
	6	piperidine, 1-[(4-chlorophenyl)acetyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	333
	7	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-(phenylacetyl)-	299
	8	piperidine, 1-(4-cyclohexylbenzoyl)-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	367

	9	piperidine, 1-[(3,4-dichlorophenyl)acetyl]-4-(1H-imidazol-4-ylmethoxy)-	367
	10	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)acetyl]-	311
	11	piperidine, 1-[(3,4-difluorophenyl)acetyl]-4-(1H-imidazol-4-ylmethoxy)-	327
	12	piperidine, 1-[(2,4-difluorophenyl)acetyl]-4-(1H-imidazol-4-ylmethoxy)-	317
	13	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(4'-propyl[1,1'-biphenyl]-4-yl)carbonyl]-	355
	14	piperidine, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-4-(1H-imidazol-4-ylmethoxy)-	329
	15	piperidine, 1-[(2E)-3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-4-(1H-imidazol-4-ylmethoxy)-	379
	16	piperidine, 1-[3-(2,4-dichlorophenyl)-1-oxopropyl]-4-(1H-imidazol-4-ylmethoxy)-	381
	17	piperidine, 1-[(2,4-dichlorophenyl)acetyl]-4-(1H-imidazol-4-ylmethoxy)-	367

5 Example 18

1-[(2-Bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine


10

To a solution of 4-[[1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]-piperidine (0.5g, 1.18mmol) and 2-bromobenzaldehyde (0.218g, 1.18mmol) in 10% acetic acid/*N*-methylpyrrolidine (10ml) was added (polystyrylmethyl)trimethylammonium cyanoborohydride resin (4.2mmol/g equivalent, 300mg). The mixture was stirred 16h at room temperature, the resin removed by filtration and the solution evaporated. The residue was purified by reserve phase HPLC on an Xterra™ column using aqueous ammonium acetate/acetonitrile as eluant to give the title compound (0.058g). MS (+APCI) *m/z* 350 (*M*+*H*⁺). 400 MHz ¹H NMR (d₆-DMSO) 7.59-7.56 (2H, m), 7.46 (1H, d), 7.36 (1H, t), 7.19 (1H, t), 7.05-6.8 (2H, br.m), 4.37 (2H, br.s), 3.50 (2H, s), 3.40 (1H, br.s), 2.71-2.66 (2H, m), 2.18-2.12 (2H, m), 1.84-1.81 (2H, m), 1.50-1.41 (2H, m)

20

Example 19









1-[(3-Bromo-2-thienyl)methyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine





















- This was prepared by the method of Example 18 using 3-bromothiophene-2-carboxaldehyde and 4-[[5-methyl-1-(triphenylmethyl)-1*H*-imidazol-4-yl]methoxy]piperidine. MS (+APCI) m/z 372 ($M+H^+$). 400 MHz 1H NMR (d_6 -DMSO) 7.57 (1H, d, J 5.4 Hz), 7.40 (1H, s), 7.02 (1H, d, J 5.4 Hz), 4.32 (2H, s), 3.61 (2H, s), 3.29 (1H, m), 2.73 (2H, m), 2.17 (2H, m), 2.11 (3H, s), 1.82 (2H, m), 1.42 (2H, m)
- 10 The compounds in Table 2 were prepared using the method of Example 18 with the appropriate acid :

Table 2










Example structure	Example no.	Name	$M+H^+$ (+APCI)
	20	piperidine, 1-[(3-bromo-2-thienyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	355
	21	piperidine, 1-[(4-ethynylphenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	295










	22	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[3-(4-methylphenoxy)phenyl]methyl]-	377
	23	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[4-(2-propenyloxy)phenyl]methyl]-	327
	24	phenol, 4-[[4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	287
	25	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[(2-methoxyphenyl)methyl]-	301
	26	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[3-(4-methoxyphenoxy)phenyl]methyl]-	393
	27	piperidine, 1-[(2,3-dichlorophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	339
	28	piperidine, 1-[(2-chloro-4-fluorophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	323
	29	piperidine, 1-(2-dibenzofuranylmethyl)-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	361










	30	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[2-(methylthio)phenyl]methyl]-	317
	31	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-(thieno[2,3- <i>b</i>][1]benzothien-2-ylmethyl)-	383
	32	piperidine, 1-[(2-chloro-5-nitrophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	350
	33	1 <i>H</i> -pyrrole, 2-[[4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-[(4-methylphenyl)sulfonyl]-	414
	34	phenol, 2-ethoxy-6-[[4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	331
	35	piperidine, 1-(1,3-benzodioxol-5-ylmethyl)-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	315
	36	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[4-(phenylmethoxy)phenyl]methyl]-	377
	37	piperidine, 1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	357










	38	piperidine, 1-[(4-bromophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	349
	39	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)methyl]-	285
	40	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-(2-thienylmethyl)-	277
	41	piperidine, 1-[(4-chlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	305
	42	piperidine, 1-[(2-chloro-6-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	323
	43	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(3-methyl-2-thienyl)methyl]-	291
	44	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-(2-naphthalenylmethyl)-	321
	45	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-(1-naphthalenylmethyl)-	321
	46	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(2-nitrophenyl)methyl]-	316
	47	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-(3-thienylmethyl)-	277










1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100










	48	piperidine, 1-([1,1'-biphenyl]-4-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	347
	49	piperidine, 1-[(2,5-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	307
	50	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(3-phenoxyphenyl)methyl]-	363
	51	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(3-methylphenyl)methyl]-	285
	52	piperidine, 1-(2-furanylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	261
	53	piperidine, 1-[(2,6-dichlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	339
	54	piperidine, 1-[(4-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	289
	55	piperidine, 1-[(3-fluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	289
	56	piperidine, 1-(3-furanylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	261




	57	piperidine, 1-[(4-ethylphenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	299
	58	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(2-methylphenyl)methyl]-	285
	59	piperidine, 1-[(3-chlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	305
	60	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(5-methyl-2-thienyl)methyl]-	291
	61	piperidine, 1-[(4-bromo-2-thienyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	355
	62	piperidine, 1-[(2,2'-bithiophen]-5-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	359
	63	phenol, 3,5-dichloro-2-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	355
	64	piperidine, 1-[(3,4-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	307
	65	piperidine, 1-[(3,5-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	307

	66	piperidine, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	349
	67	piperidine, 1-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-4-(1H-imidazol-4-ylmethoxy)-	410
	68	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(1-methyl-1H-pyrrol-2-yl)methyl]-	274
	69	1H-indole, 3-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-(phenylmethyl)-	400
	70	piperidine, 1-[(5-chloro-2-thienyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	311
	71	piperidine, 1-(1,3-benzodioxol-4-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	315
	72	2-thiophenecarbonitrile, 3-[[4-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]phenoxy]methyl]-	408
	73	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[[5-(phenylethynyl)-2-thienyl]methyl]-	377
	74	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[[5-(4-nitrophenyl)-2-	382

	75	furanyl]methyl]- piperidine, 4-(1 <i>H</i> - imidazol-4-ylmethoxy)-1- [[5-(3-nitrophenyl)-2- furanyl]methyl]-	382
	76	piperidine, 1-[(4-chloro- 1 <i>H</i> -pyrazol-3-yl)methyl]- 4-(1 <i>H</i> -imidazol-4- ylmethoxy)-	295
	77	piperidine, 1-[(4-bromo- 1-methyl-1 <i>H</i> -pyrazol-3- yl)methyl]-4-(1 <i>H</i> - imidazol-4-ylmethoxy)-	353
	78	piperidine, 1-[(4-bromo- 1 <i>H</i> -pyrazol-3-yl)methyl]- 4-(1 <i>H</i> -imidazol-4- ylmethoxy)-	339
	79	benzonitrile, 2-[[4-(1 <i>H</i> - imidazol-4-ylmethoxy)-1- piperidinyl]methyl]-	296
	80	piperidine, 4-(1 <i>H</i> - imidazol-4-ylmethoxy)-1- [(4-iodophenyl)methyl]-	397
	81	piperidine, 1-[(5-ethyl-2- thienyl)methyl]-4-(1 <i>H</i> - imidazol-4-ylmethoxy)-	305
	82	piperidine, 4-(1 <i>H</i> - imidazol-4-ylmethoxy)-1- [[5-(methylthio)-2- thienyl]methyl]-	323
	83	piperidine, 1-[[1-(3,5- dichlorophenyl)-1 <i>H</i> - pyrrol-2-yl]methyl]-4- (1 <i>H</i> -imidazol-4- ylmethoxy)-	404

	84	piperidine, 1-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]-4-(1H-imidazol-4-ylmethoxy)-	370
	85	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[[4-(phenylethynyl)-2-thienyl]methyl]-	377
	86	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(3-phenoxy-2-thienyl)methyl]-	369
	87	piperidine, 1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-(1H-imidazol-4-ylmethoxy)-	373
	88	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[(4-propoxyphenyl)methyl]-	329
	89	phenol, 2-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	287
	90	piperidine, 1-[(2,4-difluorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	307
	91	2-thiophenecarbonitrile, 3-[[4-(1H-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	302
	92	piperidine, 1-(benzo[b]thien-3-ylmethyl)-4-(1H-imidazol-4-ylmethoxy)-	327

	93	pyridine, 2-chloro-3-[[4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-	306
	94	phenol, 3-[[4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-(2-propenyl)-	327
	95	piperidine, 1-[(4-chloro-3-fluorophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	323
	96	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[[4-(trifluoromethoxy)phenyl]methyl]-	355
	97	piperidine, 1-[(2,6-difluorophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	307
	98	piperidine, 1-[(4-bromo-2-fluorophenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	367
	99	piperidine, 1-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	351
	100	piperidine, 1-[(4-butoxyphenyl)methyl]-4-(1 <i>H</i> -imidazol-4-ylmethoxy)-	343
	101	piperidine, 4-(1 <i>H</i> -imidazol-4-ylmethoxy)-1-[(2,3,5-	373

		trichlorophenyl)methyl]-	
	102	piperidine, 1-[(2,5-dichlorophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	339
	103	piperidine, 4-(1H-imidazol-4-ylmethoxy)-1-[[2-(trifluoromethyl)phenyl]methyl]-	339
	104	piperidine, 1-[(4-chloro-2-nitrophenyl)methyl]-4-(1H-imidazol-4-ylmethoxy)-	350

Pharmacological Data

H4-CHO FLUOROMETRIC IMAGING PLATE READER (FLIPR) ASSAY

5 FLIPR was employed to measure the intracellular calcium mobilisation to H4 receptor activation by histamine. CHO-K1 cells expressing the human recombinant H4 receptor with G α 16 were purchased from Euroscreen and used in the experiments to identify H4 antagonists. The same protocol was used with the human H3-CHO cell line (Euroscreen) to determine selectivity of the H4 antagonists.

10

Briefly, the FLIPR protocol detects changes in $[Ca^{2+}]_i$ using Fluo-3AM loaded cells (Schroeder & Neagle. FLIPR: A new instrument for accurate, high throughput optical screening. *J. Biomol. Screening*: 1(2), 75-80, 1996.). The H4-CHO cells were cultured routinely in T225cm² tissue culture flasks as monolayers in NUT Hams (with 1% (v/v) 15 Glutamine) supplemented with 10% (v/v) heat inactivated foetal bovine serum and grown under Geneticin (1mg/ml) antibiotic selection & 1mg/ml Zeocin selection. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂ and passaged every 3 days.


H4-CHO cells were seeded at 10,000 cells/well (384 FLIPR plate) 18-24hr before the 20 experiment. Cells were washed to remove medium and replaced with loading buffer for 1.5 hrs. The loading buffer contains Hanks balance salt solution (Sigma), HEPES (20 mM), probenecid (2.5 mM) and Fluo 3-AM (4 μ M) /Brilliant Black at pH7.4. The EC50 of histamine was determined on the day of the experiment and 2X EC50 was chosen as the dose to test compounds against. ATP stimulation was included in the FLIPR assay to 25 exclude any non-selective antagonists.

Step by step guide to FLIPR assay

1. Cells were harvested using 1x dissociation solution and plated onto poly-D-lysine coated FLIPR 384 plates at 1.0×10^4 cells per well 18-24 hours prior to experiment.

2. Media was removed from the cells by tipping the plates and gently blotted onto tissue to remove any excess medium.
3. 30 μ l loading buffer was added to all wells and plates were incubated for 90 min at 37°C.
- 5 4. 96 well histamine EC₅₀ plate was made and then 40 μ l was indexed into 4 quadrants in a 384 well plate.
5. 96 well compound vehicle (1% DMSO) plate was made and indexed into a quadrant of a 384 well plate.
6. Plates transferred to FLIPR and run using protocol attached (see Appendix 1)
- 10 7. EC₅₀ for histamine was calculated.
8. 96 well histamine plate (x10 EC₅₀) was made and then 60 μ l was indexed into 4 quadrants in a 384 well plate.
9. Each 96 well compound plate was made and indexed into a quadrant of a 384 well plate.
- 15 10. ATP plate was made in a 96 well plate and then 60 μ l was indexed into 4 quadrants in a 384 well plate.
11. Plates transferred to FLIPR and run using protocol attached (see Appendix 1)
 - Cell media (but not cells) removed from FLIPR 384 plate
 - 30 μ l of loading buffer added to FLIPR 384 plate
 - 20 • 10 μ l compound added to cell plate
 - Reads taken for 5min to determine compound effects
 - 10 μ l histamine added to cell plate
 - Reads taken to determine histamine response
 - 10 μ l ATP added to cell plate
 - 25 • Reads taken for 5min to determine ATP response
12. Final assay concentrations
 - Compound concentration range = 30 μ M to 0.01 μ M
 - histamine= 2x calculated EC₅₀
 - ATP = 11 μ M

5

Example of FLIPR traceA = Compound additionB = Histamine additionC = ATP addition


10

Appendix 1**384 well FLIPR protocol****General**

5	Exposure	0.4
	Filter	1
	Presoak	None
	Second Sequence	Yes
	Third Sequence	YES
10	Auto prompt for notes	No
	Auto print	Yes
	Auto export time sequence	Yes
	Auto export stats	Yes
First sequence (Compound)		
15	Initial interval	20 readings every 2sec
	Second interval	27 readings every 10sec
	Fluid Addition	
20	Addition Active	Yes
	Volume	10.0
	After Sample	5
	Height	25
	Speed	15.0
	Mix	No
Second sequence (histamine)		
25	Initial interval	20 readings every 2sec
	Second interval	12 readings every 10sec
	Fluid Addition	
30	Addition Active	Yes
	Volume	10.0
	After Sample	3
	Height	35
	Speed	15.0
	Mix	No
Third sequence (ATP)		
35	Initial interval	20 readings every 2sec
	Second interval	12 readings every 10sec
	Fluid Addition	
40	Addition Active	Yes
	Volume	10.0
	After Sample	3
	Height	35
	Speed	40.0
	Mix	No
Pipetting		
45	Mix Volume	0.0
	Mix Cycles	0
	Leave tips in well	No
	Remove fluid after addition	No
	Stage heated to 35°C	
50	The compounds of the examples have an IC ₅₀ vs H4 of <10 micromolar.	

CLAIMS

1. A compound of formula (I) and pharmaceutically acceptable salts and solvates thereof for use in the manufacture of a medicament for the treatment of diseases mediated by histamine H3 and H4:



(I)

in which:

Ar is an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which can be optionally substituted by 1-3 groups selected from C₁₋₆ alkyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, halogen, cyano, CF₃, OCF₃, C₃₋₆ cyclolalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₆ alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R¹ is hydrogen or C₁₋₆ alkyl;

X is O, NR², CH₂ or SO_x

R² is C₁₋₆ alkyl;

x is 0, 1 or 2;

Y is CH₂, C=O, SO₂, or (C=O)NH;

Z is (CR³R⁴)_r or Y and Z together form a CH=CH group;

m and n are independently 0, 1, 2 or 3;

p and q are independently 0, 1 or 2;

r is 0, 1, 2, 3, or 4 and

5 R^3 and R^4 are independently hydrogen or C_{1-6} alkyl.

2. A compound according to claim 1 in which Ar^1 is phenyl optionally substituted as defined above. Preferred substituents include halogen such as iodo, chloro and fluoro, cyclohexyl, methyl, ethyl, propyl, t-butyl, ethynyl, propenyloxy, hydroxyl, methoxy, nitro,
10 tosyl, trifluoromethyl, thienyl, benzyl, cyano, phenylethynyl, nitrophenyl, methylthio, propoxy, butoxy, 2-propenyl, or trifluomethoxy.

3. A compound according to claim 1 or 2 in which R^1 is hydrogen or methyl.

15 4. A compound according to any one of claims 1 to 3 in which X is O.

5. A compound according to any one of claims 1 to 4 in which Y is CH_2 or $C=O$ and Z is CH_2 , $CHMe$, CH_2CHMe or Y and Z form a $CH=CH$ group.

20 6. A compound according to any one of claims 1 to 5 in which m is 1 and n is 0.

7. A compound according to any one of claims 1 to 6 in which p and q are both 1.

8. A compound of formula (I) selected from:

25 4-(1*H*-Imidazol-4-ylmethoxy)-1-(1-oxo-3-phenylbutyl)-piperidine

4-(1*H*-Imidazol-4-ylmethoxy)-1-[[4-(trifluoromethyl)phenyl]acetyl]-piperidine

1-[2-(4-Hydroxyphenyl)-1-oxopropyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-
piperidine

1-[(4-fluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

30 1-[(2-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

1-[(4-chlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

4-(1*H*-imidazol-4-ylmethoxy)-1-(phenylacetyl)-piperidine

1-(4-cyclohexylbenzoyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

1-[(3,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine


- 4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)acetyl]-piperidine
 1-[(3,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(2,4-difluorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[(4'-propyl[1,1'-biphenyl]-4-yl)carbonyl]-piperidine
 5 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(2*E*)-3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-4-(1*H*-imidazol-4-ylmethoxy)-
 piperidine
 1-[3-(2,4-dichlorophenyl)-1-oxopropyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(2,4-dichlorophenyl)acetyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 10 1-[(2-Bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(3-Bromo-2-thienyl)methyl]-4-[(5-methyl-1*H*-imidazol-4-yl)methoxy]-piperidine
 1-[(3-bromo-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(4-ethynylphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-(4-methylphenoxy)phenyl]methyl]-piperidine
 15 4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(2-propenyloxy)phenyl]methyl]-piperidine
 4-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
 4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-methoxyphenyl)methyl]-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[3-(4-methoxyphenoxy)phenyl]methyl]-piperidine
 1-[(2,3-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 20 1-[(2-chloro-4-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-(2-dibenzofuranylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[2-(methylthio)phenyl]methyl]-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-(thieno[2,3-*b*][1]benzothien-2-ylmethyl)-piperidine
 1-[(2-chloro-5-nitrophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 25 1*H*-pyrrole, 2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-[(4-
 methylphenyl)sulfonyl]-
 2-ethoxy-6-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
 1-(1,3-benzodioxol-5-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(phenylmethoxy)phenyl]methyl]-piperidine
 30 1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

- 1-[(4-bromophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-methylphenyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(2-thienylmethyl)-piperidine
1-[(4-chlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
5 1-[(2-chloro-6-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-methyl-2-thienyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(2-naphthalenylmethyl)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-(1-naphthalenylmethyl)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-nitrophenyl)methyl]-piperidine
10 4-(1*H*-imidazol-4-ylmethoxy)-1-(3-thienylmethyl)-piperidine
1-[(1,1'-biphenyl)-4-ylmethyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2,5-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-phenoxyphenyl)methyl]-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-methylphenyl)methyl]-piperidine
15 1-(2-furanylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(2,6-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(4-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(3-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-(3-furanylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
20 1-[(4-ethylphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(2-methylphenyl)methyl]-piperidine
1-[(3-chlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
4-(1*H*-imidazol-4-ylmethoxy)-1-[(5-methyl-2-thienyl)methyl]-piperidine
1-[(4-bromo-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
25 1-[(2,2'-bithiophen)-5-ylmethyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
3,5-dichloro-2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
1-[(3,4-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(3,5-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine

- 1-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[(1-methyl-1*H*-pyrrol-2-yl)methyl]-piperidine
- 1*H*-indole, 3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-1-(phenylmethyl)-
- 5 1-[(5-chloro-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 1-(1,3-benzodioxol-4-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 2-thiophenecarbonitrile, 3-[[4-[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]phenoxy]methyl]-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(phenylethynyl)-2-thienyl]methyl]-piperidine
- 10 4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(4-nitrophenyl)-2-furanyl]methyl]-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(3-nitrophenyl)-2-furanyl]methyl]-piperidine
- 1-[(4-chloro-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 1-[(4-bromo-1-methyl-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 1-[(4-bromo-1*H*-pyrazol-3-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 15 2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-benzonitrile
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-iodophenyl)methyl]-piperidine
- 1-[(5-ethyl-2-thienyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[[5-(methylthio)-2-thienyl]methyl]-piperidine
- 1-[[1-(3,5-dichlorophenyl)-1*H*-pyrrol-2-yl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-
- 20 piperidine
- 1-[[1-(4-chlorophenyl)-1*H*-pyrrol-2-yl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(phenylethynyl)-2-thienyl]methyl]-piperidine
- 4-(1*H*-imidazol-4-ylmethoxy)-1-[(3-phenoxy-2-thienyl)methyl]-piperidine
- 1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 25 4-(1*H*-imidazol-4-ylmethoxy)-1-[(4-propoxyphenyl)methyl]-piperidine
- 2-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-phenol
- 1-[(2,4-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-thiophenecarbonitrile
- 1-(benzo[*b*]thien-3-ylmethyl)-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
- 30 2-chloro-3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-pyridine

3-[[4-(1*H*-imidazol-4-ylmethoxy)-1-piperidinyl]methyl]-2-(2-propenyl)-phenol
 1-[(4-chloro-3-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[4-(trifluoromethoxy)phenyl]methyl]-piperidine
 1-[(2,6-difluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(4-bromo-2-fluorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 1-[(4-butoxyphenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[(2,3,5-trichlorophenyl)methyl]-piperidine
 1-[(2,5-dichlorophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 4-(1*H*-imidazol-4-ylmethoxy)-1-[[2-(trifluoromethyl)phenyl]methyl]-piperidine
 1-[(4-chloro-2-nitrophenyl)methyl]-4-(1*H*-imidazol-4-ylmethoxy)-piperidine
 and pharmaceutically acceptable salts and solvates thereof.

9. A compound of formula (IA):



in which:

Ar is an aryl group, a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, or a bicyclic or tricyclic heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, each of which can be optionally substituted by 1-3 groups selected from C₁₋₆ alkyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, halogen, cyano, CF₃, OCF₃, C₃₋₆ cyclolalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₆ alkenyloxy, hydroxyl, nitro, tosyl, thienyl, benzyl, phenyl, nitrophenyl,

R¹ is hydrogen or C₁₋₆ alkyl;

X is O, NR², CH₂ or SO_x

R^2 is C_{1-6} alkyl;

x is 0, 1 or 2;

5 Y is $C=O$, SO_2 , or $(C=O)NH$;

Z is $(CR^3R^4)_r$, or Y and Z together form a $CH=CH$ group;

m and n are independently 0, 1, 2 or 3;

10

p and q are independently 0, 1 or 2;

r is 0, 1, 2, 3, or 4, and

15 R^3 and R^4 are independently hydrogen or C_{1-6} alkyl.

10. A compound according to claim 9 in which Y is $C=O$.

11. A pharmaceutical composition comprising a compound of formula (IA), or a
20 pharmaceutically acceptable salt or solvate thereof, as claimed in claim 10 or 11 in
association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A compound of formula (IA), or a pharmaceutically acceptable salt or solvate thereof,
as claimed in claim 10 or 11 for use in therapy.

25

13. Use of a compound of formula (IA), or a pharmaceutically acceptable salt or
solvate thereof, as claimed in claim 10 or 11 in the manufacture of a medicament for use in
therapy.

30

14. Use of a compound of formula (IA), or a pharmaceutically acceptable salt or
solvate thereof, as claimed in claim 10 or 11 in the manufacture of a medicament for use as
a histamine H_4 antagonist.

35

15. A compound of formula (IA) for use in the treatment of a disease where
modulation of histamine H_4 activity is beneficial.

ABSTRACT

5

The invention relates to piperidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.